



an Open Access Journal by MDPI

## Drug Discovery Targeting the Hippo Signaling Pathway

Guest Editors:

### **Dr. Ajaybabu V. Pobbati**

1. Department of Cancer Biology,  
Lerner Research Institute,  
Cleveland Clinic Foundation,  
Cleveland, OH 44195, USA  
2. Department of Molecular  
Medicine, Cleveland Clinic Lerner  
College of Medicine, Case  
Western Reserve University,  
Cleveland, OH 44195, USA

### **Dr. Iris Valtingojer**

Sanofi Oncology Research  
Therapeutic Area, 1, impasse des  
Ateliers, 94400 Vitry-sur-Seine,  
France

Deadline for manuscript  
submissions:

**closed (28 June 2023)**

### **Message from the Guest Editors**

Dear Colleagues,

As the role of the Hippo signaling pathway in cancer and tissue regeneration becomes apparent, small molecules that target the components of this pathway are increasingly being developed and tested for their utility in cancer therapy and regenerative medicine. The druggability of kinases is well established; therefore, two core kinases in this pathway, MST1/2 and LATS1/2, are targeted. Interestingly, the TEAD family of transcription factors has emerged as a novel target.

This Special Issue aims to attract manuscripts describing hits and screens, which, when disseminated to the community, result in the development of more favorable pharmaceuticals through collective effort. We are also interested in manuscripts that identify novel druggable targets of the Hippo pathway. Topics that highlight other disease indications where Hippo modulators can be used also fall within the scope of this Special Issue.

Dr. Ajaybabu V. Pobbati

Dr. Iris Valtingojer

*Guest Editors*



[mdpi.com/si/134497](https://mdpi.com/si/134497)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)